Literature DB >> 19060209

HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells.

Marta Catalfamo1, Michele Di Mascio, Zonghui Hu, Sharat Srinivasula, Vishakha Thaker, Joseph Adelsberger, Adam Rupert, Michael Baseler, Yutaka Tagaya, Gregg Roby, Catherine Rehm, Dean Follmann, H Clifford Lane.   

Abstract

HIV infection is characterized by a brisk immune activation that plays an important role in the CD4 depletion and immune dysfunction of patients with AIDS. The mechanism underlying this activation is poorly understood. In the current study, we tested the hypothesis that this activation is the net product of two distinct pathways: the inflammatory response to HIV infection and the homeostatic response to CD4 T cell depletion. Using ex vivo BrdU incorporation of PBMCs from 284 patients with different stages of HIV infection, we found that CD4 proliferation was better predicted by the combination of CD4 depletion and HIV viral load (R(2) = 0.375, P < 0.001) than by either parameter alone (CD4 T cell counts, R(2) = 0.202, P < 0.001; HIV viremia, R(2) = 0.302, P < 0.001). Interestingly, CD8 T cell proliferation could be predicted by HIV RNA levels alone (R(2) = 0.334, P < 0.001) and this predictive value increased only slightly (R(2) = 0.346, P < 0.001) when CD4 T cell depletion was taken into account. Consistent with the hypothesis that CD4 T cell proliferation is driven by IL-7 as a homeostatic response to CD4 T cell depletion, levels of phosphorylated STAT-5 were found to be elevated in naive subsets of CD4 and CD8 T cells from patients with HIV infection and in the central memory subset of CD4 T cells. Taken together these data demonstrate that at least two different pathways lead to immune activation of T cells in patients with HIV infection and these pathways differentially influence CD4 and CD8 T cell subsets.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19060209      PMCID: PMC2596741          DOI: 10.1073/pnas.0810032105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis.

Authors:  L A Napolitano; R M Grant; S G Deeks; D Schmidt; S C De Rosa; L A Herzenberg; B G Herndier; J Andersson; J M McCune
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

2.  Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients.

Authors:  R A Lempicki; J A Kovacs; M W Baseler; J W Adelsberger; R L Dewar; V Natarajan; M C Bosche; J A Metcalf; R A Stevens; L A Lambert; W G Alvord; M A Polis; R T Davey; D S Dimitrov; H C Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 3.  The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance.

Authors:  Terry J Fry; Crystal L Mackall
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

4.  Cytosolic tyrosine dephosphorylation of STAT5. Potential role of SHP-2 in STAT5 regulation.

Authors:  C L Yu; Y J Jin; S J Burakoff
Journal:  J Biol Chem       Date:  2000-01-07       Impact factor: 5.157

5.  Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen.

Authors:  N Sachsenberg; A S Perelson; S Yerly; G A Schockmel; D Leduc; B Hirschel; L Perrin
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

Review 6.  T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock.

Authors:  M D Hazenberg; D Hamann; H Schuitemaker; F Miedema
Journal:  Nat Immunol       Date:  2000-10       Impact factor: 25.606

7.  Peripheral S-phase T cells in HIV disease have a central memory phenotype and rarely have evidence of recent T cell receptor engagement.

Authors:  Scott F Sieg; Benigno Rodriguez; Robert Asaad; Wei Jiang; Douglas A Bazdar; Michael M Lederman
Journal:  J Infect Dis       Date:  2005-05-26       Impact factor: 5.226

8.  Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage.

Authors:  J V Giorgi; L E Hultin; J A McKeating; T D Johnson; B Owens; L P Jacobson; R Shih; J Lewis; D J Wiley; J P Phair; S M Wolinsky; R Detels
Journal:  J Infect Dis       Date:  1999-04       Impact factor: 5.226

9.  Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection.

Authors:  Marc K Hellerstein; Rebecca A Hoh; Mary Beth Hanley; Denise Cesar; Daniel Lee; Richard A Neese; Joseph M McCune
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

10.  CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection.

Authors:  Jean-Marc Doisne; Alejandra Urrutia; Christine Lacabaratz-Porret; Cécile Goujard; Laurence Meyer; Marie-Laure Chaix; Martine Sinet; Alain Venet
Journal:  J Immunol       Date:  2004-08-15       Impact factor: 5.422

View more
  72 in total

Review 1.  The role of cytokines in the pathogenesis and treatment of HIV infection.

Authors:  Marta Catalfamo; Cecile Le Saout; H Clifford Lane
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-26       Impact factor: 7.638

Review 2.  Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010.

Authors:  James D Neaton; Jacqueline Neuhaus; Sean Emery
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

3.  The CD8+ HLA-DR+ T cells expanded in HIV-1 infection are qualitatively identical to those from healthy controls.

Authors:  Hiromi Imamichi; Richard A Lempicki; Joseph W Adelsberger; Rebecca B Hasley; Alice Rosenberg; Gregg Roby; Catherine A Rehm; Amy Nelson; Sonya Krishnan; Mark Pavlick; Christian J Woods; Michael W Baseler; H Clifford Lane
Journal:  Eur J Immunol       Date:  2012-08-06       Impact factor: 5.532

4.  Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy.

Authors:  Hiromi Imamichi; Robin L Dewar; Joseph W Adelsberger; Catherine A Rehm; Una O'Doherty; Ellen E Paxinos; Anthony S Fauci; H Clifford Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-18       Impact factor: 11.205

Review 5.  Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection.

Authors:  Denise C Hsu; Irini Sereti
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

6.  Carbohydrate-functionalized nanovaccines preserve HIV-1 antigen stability and activate antigen presenting cells.

Authors:  J E Vela Ramirez; R Roychoudhury; H H Habte; M W Cho; N L B Pohl; B Narasimhan
Journal:  J Biomater Sci Polym Ed       Date:  2014-07-28       Impact factor: 3.517

7.  Decreases in IL-7 levels during antiretroviral treatment of HIV infection suggest a primary mechanism of receptor-mediated clearance.

Authors:  Jessica N Hodge; Sharat Srinivasula; Zonghui Hu; Sarah W Read; Brian O Porter; Insook Kim; Joann M Mican; Chang Paik; Paula Degrange; Michele Di Mascio; Irini Sereti
Journal:  Blood       Date:  2011-07-21       Impact factor: 22.113

8.  Differential effects of HIV viral load and CD4 count on proliferation of naive and memory CD4 and CD8 T lymphocytes.

Authors:  Sharat Srinivasula; Richard A Lempicki; Joseph W Adelsberger; Chiung-Yu Huang; Joshua Roark; Philip I Lee; Adam Rupert; Randy Stevens; Irini Sereti; H Clifford Lane; Michele Di Mascio; Joseph A Kovacs
Journal:  Blood       Date:  2011-05-11       Impact factor: 22.113

9.  Association of T Cell and Macrophage Activation with Arterial Vascular Health in HIV.

Authors:  Heather N Grome; Louise Barnett; Cindy C Hagar; David G Harrison; Spyros A Kalams; John R Koethe
Journal:  AIDS Res Hum Retroviruses       Date:  2016-09-14       Impact factor: 2.205

10.  Understanding the HIV coreceptor switch from a dynamical perspective.

Authors:  Christel Kamp
Journal:  BMC Evol Biol       Date:  2009-11-30       Impact factor: 3.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.